U.S. FDA Clears Ascletis Pharma Inc.’s Application for Oral IL-17 Blocker in Psoriasis
The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for Ascletis Pharma Inc.’s ASC50 for the treatment of mild-to-moderate plaque psoriasis.